What a well-run taper looks like

Everything on this site about tapering harm gets misread in one predictable direction, so let us be direct: tapering is sometimes the right thing to do, and none of the researchers cited here says otherwise.

What the evidence argues against is a specific version of it — fast, imposed, triggered by a number rather than by the patient, and carried out without anywhere for the patient to go afterwards.

When a reduction is indicated

• Benefit no longer exceeds risk for this patient — function is not being maintained, or harms have emerged.
• The patient wants to reduce. This is more common than the debate suggests, and it produces much better outcomes than an imposed reduction.
• A specific safety concern has appeared — new sedating co-medication, a change in respiratory status, evidence of a developing use disorder that needs treatment rather than removal.

What good practice looks like

A consensus panel published in Mayo Clinic Proceedings set out patient protections for tapering, and it remains the most useful practical document in this area. Distilled:

1. Collaborative. Agreed with the patient, not announced to them. A taper the patient has not agreed to is a different intervention with different outcomes.
2. Slow. The dose-response finding matters here — faster tapers were associated with worse outcomes, with each 10% increase in monthly reduction velocity associated with an adjusted incidence rate ratio of 1.09 for overdose and 1.18 for mental health crisis.
3. Reversible. Pause or reverse when the patient deteriorates. A taper that only goes one direction is not a clinical process.
4. Supported. With behavioral health available, with the non-opioid components of the plan actually in place rather than mentioned, and with more contact rather than less.
5. Never a condition of care. Refusing a taper must not result in dismissal. CDC states this directly.

What CDC says

The 2022 guideline: “Unless there are indications of a life-threatening issue such as warning signs of impending overdose… opioid therapy should not be discontinued abruptly, and clinicians should not rapidly reduce opioid dosages from higher dosages.” And: clinicians “should avoid dismissing patients from care, and should ensure (provide or arrange) appropriate care for patients with pain and patients with complications from opioid use.”

It also records FDA’s advice that rapid tapering or sudden discontinuation in physically dependent patients risks acute withdrawal, exacerbation of pain, serious psychological distress and thoughts of suicide.

The question to ask about any taper policy

Who decided, and on the basis of what? If the answer is “a threshold decided, on the basis of a converted dose,” the policy is the thing the evidence is about. If the answer is “the clinician and the patient decided, on the basis of how this patient is doing,” it is not.

More: the tapering evidence · the stranded population.